Walton Oaks, 7th October 2024 - Pfizer Ltd has announced that John McGinley has been appointed UK Managing Director and Country President, formally taking over from Susan Rienow who was appointed Pfizer’s Global Chief Marketing Officer in July.

John joined Pfizer in 2011 and has been leading the UK Primary Care division since November 2023, a role which has most recently involved supporting DHSC,^* UKHSA^† and the NHS with the implementation of a national immunisation programme. He has acted as Interim UK Country President for the past two months and he has been a member of the ABPI^‡  board since February 2024.   

Commenting on his appointment, John said: “It is a privilege to take on this responsibility, knowing that every year millions of people rely on Pfizer medicines and vaccines across the UK. While our country undoubtedly faces persistent and growing healthcare challenges, I believe that Pfizer has the science, scale and experience to support in tackling these and easing the associated economic and societal pressures. We have shown that we can move with urgency to deliver scientific breakthroughs and we remain committed to working with our partners across the life sciences to better manage disease, free up healthcare services and help people live healthier and more prosperous lives.”

During her two and a half years as head of the UK organisation, Susan successfully oversaw the approval of multiple innovative vaccines and treatments for routine use on the NHS and an important agreement with NHS England under the UK Antimicrobial Resistance Reimbursement Pilot. While acting as both Managing Director of Pfizer UK and as President of the ABPI, Susan has also worked tirelessly to further the industry’s mission of making the UK the best place in the world to research, develop and access medicines and vaccines to improve patient care. This has included steering negotiations between industry and Government in relation to the sales levy applied to branded medicines, known as the Value, Access, Pricing and Growth Scheme (VPAG).

Reflecting on her tenure, Susan said: “I am proud of everything we have managed to achieve as a company over the course of our history in the UK but particularly the contribution we have made to society in the past few years. We have been able to really demonstrate the value the sector brings and what is possible when partners from across the life sciences and healthcare have a truly shared purpose and common goal. Future success will depend on our ability to learn from experience, as well as continued collaborations.”
 

For all media enquiries, please contact:
Pfizer UK Press Office
Tel: 0845 300 8033
Email: [email protected]


About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS. To learn more about our commitments, please visit us at www.pfizer.co.uk or follow us on X (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).